Search

Search Results

1. Recent advances and future perspectives in the therapeutics of prostate cancer

   Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic...

   Ganji Lakshmi Varaprasad, Vivek Kumar Gupta, ... Yun Suk Huh in Experimental Hematology & Oncology

   Article Open access 22 September 2023
   

2. Multiple drugs

   in Reactions Weekly

   Article 04 March 2023

3. Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

   Purpose of Review

   [ ¹⁷⁷ Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen...

   Daria Arbuznikova, Matthias Eder, ... Ann-Christin Eder in Current Oncology Reports

   Article Open access 20 October 2023
   

4. Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization

   Due to cancer’s complex nature and variable response to therapy, precision oncology informed by omics sequence analysis has become the current...

   Patrick J. Lawrence, Benjamin Burns, **a Ning in npj Precision Oncology

   Article Open access 18 May 2024
   

5. Theranostics in prostaatkanker

   ¹⁷⁷ Lu-PSMA is a novel therapy in patients with metastatic castration-resistant prostate carcinoma (mCRPC). The radiolabeled drug is administered...

   Bastiaan M. Privé, Constantijn H. J. Muselaers, ... James Nagarajah in Tijdschrift voor Urologie

   Article Open access 28 February 2024
   

6. Neue Tracer und Kombinationen bei der Radioligandentherapie des Prostatakarzinoms

   Background

   ¹⁷⁷ Lutetium radioligand therapy directed against the prostate-specific membrane antigen (PSMA) is a new approved option for the treatment...

   Robert Tauber, Lukas Lunger, ... Jürgen E. Gschwend in Die Urologie

   Article 15 June 2023

7. Genitourinary cancers—best of ASCO 2020

   The aim of this short review is to summarize “clinical practice changing” abstracts about genitourinary cancers from this year’s ASCO Annual Meeting....

   Renate Pichler, Gennadi Tulchiner, Jasmin Bektic in memo - Magazine of European Medical Oncology

   Article Open access 11 December 2020
   

8. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer

   Purpose of Review

   Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for...

   Michael Sun, Muhammad Junaid Niaz, ... Scott T. Tagawa in Current Oncology Reports

   Article 29 March 2021
   

9. Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer

   Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer...

   Takahiro Kirisawa, Eijiro Nakamura, ... Yoshiyuki Matsui in International Cancer Conference Journal

   Article 21 December 2023
   

10. Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer

    Introduction

    Although the growing treatment landscape for metastatic prostate cancer (mPC) has revealed new opportunities, it has also provided...

    Andreas Ihrig, Pascal Marino Pernt, ... Imad Maatouk in International Urology and Nephrology

    Article Open access 19 July 2023

11. Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice

    The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now...

    Giandomenico Roviello, Martina Catalano, ... Lorenzo Antonuzzo in Medical Oncology

    Article 14 July 2022
    

12. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists

    Nephrotoxicity is one of the most important complications in cancer patients. In particular, acute kidney injury (AKI) is known to be associated with...

    Takeshi Matsubara, Hideki Yokoi, ... Motoko Yanagita in International Journal of Clinical Oncology

    Article 05 March 2023

13. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

    Introduction

    Prostate cancer (PC) is the second most common cancer, and the fifth most common cause of cancer-related mortality among male patients,...

    Andrea Leith, Jeri Kim, ... Sameer R. Ghate in Advances in Therapy

    Article Open access 22 March 2022
    

14. Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan

    Background

    Risk management in the post-marketing phase is crucial to minimize health problems caused by drugs. Because ethnic factors may affect drug...

    Shinobu Uzu, Jun Sato, ... Takahiro Nonaka in BMC Health Services Research

    Article Open access 26 October 2022
    

15. Die Daten im Kontext der Kongresssaison

    Mark Schrader in Uro-News

    Article 08 November 2022
    

16. Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report

    Background

    Precision medicine based on genomic analysis of germline or tumor tissue is attracting attention. However, there is no consensus on how to...

    Hiroshi Hongo, Takeo Kosaka, ... Mototsugu Oya in Diagnostic Pathology

    Article Open access 13 January 2020
    

17. Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report

    A 71-year-old man with bone metastasis of hormone-sensitive prostate cancer was treated with androgen deprivation therapy and apalutamide. Radium-223...

    Yusuke Hoshino, Kent Kanao, ... Masafumi Oyama in International Cancer Conference Journal

    Article Open access 18 April 2024
    

18. Antineoplastics

    in Reactions Weekly

    Article 13 August 2022

19. Antineoplastics

    in Reactions Weekly

    Article 24 September 2022

20. Systemic therapy response evaluation in prostate carcinoma with [⁶⁸Ga]Ga-PSMA-11 PET/CT

    Background

    Consensus statements was published by EAU and EANM to clarify some uncertainties on PSMA PET/CT response assessment in 2020. We aimed to...

    Kadir Alper Kucuker, Zeynep Yapar, ... Semra Paydas in Egyptian Journal of Radiology and Nuclear Medicine

    Article Open access 08 August 2022